Yesterday marked the expiration of the antitrust waiting period for Waltham, MA-based PerkinElmer’s (NYSE: [[ticker:PKI]]) planned acquisition of Cambridge’s ViaCell (NASDAQ: [[ticker:VIAC]]). The $300 million deal, announced about three weeks ago, boosted ViaCell’s shares more than 50 percent, and should close later this quarter.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
